Carlsmed, Inc. (CARL)

Market Cap	319.56M
Revenue (ttm)	56.44M +74.9%
Net Income	-32.60M
EPS	-1.64
Shares Out	27.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	217,620
Open	11.41
Previous Close	11.29
Day's Range	10.94 - 12.12
52-Week Range	8.50 - 17.19
Beta	n/a
Analysts	Strong Buy
Price Target	18.40 (+56.53%)
Earnings Date	May 5, 2026

About CARL

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jul 23, 2025
• Employees: 127
• Stock Exchange: NASDAQ
• Ticker Symbol: CARL
• Website: https://carlsmed.com

Financial Performance

In 2025, Carlsmed's revenue was $50.51 million, an increase of 85.94% compared to the previous year's $27.17 million. Losses were -$30.22 million, 21.6% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for CARL stock is "Strong Buy." The 12-month stock price target is $18.4, which is an increase of 56.53% from the latest price.

Price Target

$18.4

(56.53% upside)

Analyst Consensus: Strong Buy